Discussion

PREDECT has the goal of investigating and characterising complex in vitro platforms that could be used in drug discovery. This collaborative consortium partners major Pharma and academic centres to asses suitability and limitations of different in vitro platforms, to position assays that may better predict the clinical efficacy of novel anticancer agents, alone or in combination. The group is focussed on three tumour types ER+ Breast, Prostate and Lung cancer. Two types of broad in vitro platforms are being assessed: (i) thin tumour slices (ii) complex to simple 3D models. The key learning from these workstreams will be presented.